Evidence map›Paper›PMID 41495817›Full record

ArticleCancer cell international2026

Methotrexate-triggered ferroptosis suppresses oral cancer progression by phosphorylated KEAP1-mediated NRF2 degradation to inhibit SLC7A11/GPX4 signaling pathway.

Chenchen Yu, Tingting Zhang, Jialu Yuan, Yijing Su, Hongli Zhang, Liqin Xu, Xiaomin Li, Jianan Cui, Rui Xu, Yan Zhou and 4 more

Abstract read
In one paragraph

Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Chenchen Yu *Department of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China.
Tingting Zhang *Department of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China.
Jialu Yuan *Department of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China.
Yijing Su *Department of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China.
Hongli ZhangDepartment of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China.
Liqin XuDepartment of Pulmonary and Critical Care Medicine, Affiliated Hospital of Nantong University, Nantong, 226001, P.R. China.
Xiaomin LiDepartment of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China.
Jianan CuiDepartment of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China.
Rui XuDepartment of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China.
Yan ZhouDepartment of Periodontology, Affiliated Nantong Stomatological Hospital of Nantong University, Nantong, 226019, P.R. China.
Hongming HuangDepartment of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China. hhmmmc@163.com.
Xiaorong ZhouDepartment of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China. zhouxiaorong@ntu.edu.cn.
Yongqiang ZhouDepartment of Oral and Maxillofacial Surgery, Affiliated Nantong Stomatological Hospital of Nantong University, Nantong, 226006, P.R. China. ntskqyyzyq@126.com.
Erhao ZhangDepartment of Immunology, Medical School of Nantong University, Nantong, 226001, P.R. China. zhangerhao@ntu.edu.cn.

Funding

China Postdoctoral Science Foundation 2022M711722National Natural Science Foundation of China 81903154The Scientific Research Program of Nantong JC2024105The Special Research Fund Project in Clinical Medicine of Nantong University (Key Project) 2024JZ024
6 · The paper itself

Abstract

backgroundOral cancer (OC) is the most common type of head and neck cancer, with a high mortality rate, and is a leading cause of cancer-related deaths worldwide. Drug-induced ferroptosis is a novel form of non-apoptotic cell death that offers a promising strategy for cancer therapy. Accumulating evidence has emphasized the significant role of methotrexate (MTX) in the treatment of many malignancies; however, its role in the ferroptosis pathway in OCs and its underlying mechanisms remain poorly understood.

methodsAfter treating the OC cells with MTX, several cellular function assays were performed, including cell proliferation, apoptosis, colony formation, and wound healing assays. Distinctive features of ferroptosis were detected, and qPCR and western blot (WB) assays were performed to validate the expression of genes and proteins related to ferroptosis pathways in MTX-treated cells. In vitro experiments were conducted to further explore the mechanisms by which MTX regulates the stability of nuclear factor erythroid 2-related factor 2 (NRF2) in OC cells. Finally, in a mouse model using MOC1 cells, some experiments were performed to demonstrate MTX-induced ferroptosis and tumor suppression.

resultsIn this study, based on in vitro and in vivo experiments, we found that MTX significantly reduced OC cell viability by inducing ferroptosis. Mechanistically, MTX administration increased the phosphorylation of Kelch-like ECH-associated protein 1 (KEAP1) at threonine 43 via activation of the ERK/MAPK signaling pathway, thereby maintaining the protein complex formed by KEAP1 and NRF2. As result of the decreased NRF2 expression, the levels of SLC7A11 and GPX4 proteins were markedly suppressed in MTX-treated OC cells, ultimately leading to the induction of ferroptosis in OC.

conclusionsOur data demonstrated that MTX-mediated activation of the ERK/KEAP1 signaling pathway significantly induced ferroptosis by inhibiting the NRF2/HO-1/SLC7A11/GPX4 axis, thereby suppressing OC progression. These findings suggest that MTX is a promising candidate for OC treatment, offering a meaningful and effective therapeutic-strategy.

Indexed as

FerroptosisKEAP1MethotrexateNRF2Oral cancer

Identifiers

PMID41495817
PMCPMC12870982

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.